JNJ

227.43

-0.17%↓

ISRG

505.16

-0.23%↓

ABT

109.25

+3.04%↑

MDT

102.64

+1.53%↑

A

133.24

+0.35%↑

JNJ

227.43

-0.17%↓

ISRG

505.16

-0.23%↓

ABT

109.25

+3.04%↑

MDT

102.64

+1.53%↑

A

133.24

+0.35%↑

JNJ

227.43

-0.17%↓

ISRG

505.16

-0.23%↓

ABT

109.25

+3.04%↑

MDT

102.64

+1.53%↑

A

133.24

+0.35%↑

JNJ

227.43

-0.17%↓

ISRG

505.16

-0.23%↓

ABT

109.25

+3.04%↑

MDT

102.64

+1.53%↑

A

133.24

+0.35%↑

JNJ

227.43

-0.17%↓

ISRG

505.16

-0.23%↓

ABT

109.25

+3.04%↑

MDT

102.64

+1.53%↑

A

133.24

+0.35%↑

Search

CareDx Inc

Open

SectorGezondheidszorg

20.54 -0.87

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

20.13

Max

20.77

Belangrijke statistieken

By Trading Economics

Inkomsten

10M

1.7M

Verkoop

13M

100M

K/W

Sectorgemiddelde

16.25

90.422

Winstmarge

1.674

Werknemers

644

EBITDA

11M

6.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-12.54% downside

Dividenden

By Dow Jones

Volgende Winsten

25 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

321M

1.1B

Vorige openingsprijs

21.41

Vorige sluitingsprijs

20.54

Nieuwssentiment

By Acuity

32%

68%

76 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 jan 2026, 22:31 UTC

Winsten

KLA Posts Higher 2Q Profit On Product and Services Sales Growth

29 jan 2026, 22:05 UTC

Winsten

Stryker Logs Higher 4Q Profit On Sales Gains

29 jan 2026, 21:54 UTC

Winsten

Visa 1Q Sales Climb on Strong Holiday Shopping -- Update

29 jan 2026, 21:36 UTC

Winsten

Visa 1Q Sales Climb on Strong Holiday Shopping

29 jan 2026, 23:57 UTC

Acquisities, Fusies, Overnames

Aluminum Corp. of China: to Hold 67% of Joint Venture With Rio Tinto

29 jan 2026, 23:56 UTC

Acquisities, Fusies, Overnames

Aluminum Corp. of China: Deal Valued at Roughly BRL4.69 Billion

29 jan 2026, 23:53 UTC

Acquisities, Fusies, Overnames

Aluminum Corp. of China Says It, Rio Tinto Propose to Buy 69% Stake in Companhia Brasileira de Aluminio S.A.

29 jan 2026, 23:51 UTC

Winsten

Correction to Intel Earnings Article on Jan. 22 -- WSJ

29 jan 2026, 23:49 UTC

Marktinformatie

Nikkei May Decline After Wall Street Tech Selloffs -- Market Talk

29 jan 2026, 23:49 UTC

Marktinformatie

Gold Rises Amid Ongoing Iran Tensions -- Market Talk

29 jan 2026, 23:47 UTC

Marktinformatie

Pro Medicus Looks Attractive Ahead of 1H Result -- Market Talk

29 jan 2026, 23:35 UTC

Winsten

Apple Posts Blowout iPhone Sales on Surging China Demand -- 2nd Update

29 jan 2026, 23:32 UTC

Marktinformatie

REA's 1H Result Could Jolt Share Price More Than Usual -- Market Talk

29 jan 2026, 23:32 UTC

Marktinformatie

Global Equities Roundup: Market Talk

29 jan 2026, 23:15 UTC

Marktinformatie
Winsten

Visa Says High Earners Still Lead Spending Growth -- Market Talk

29 jan 2026, 22:27 UTC

Winsten

Sandisk Beats Earnings. The Stock Is Soaring. -- Barrons.com

29 jan 2026, 22:27 UTC

Winsten

GE Vernova Gains After Earnings. Guidance Boost Was Enough to Lift the Stock. -- Barrons.com

29 jan 2026, 22:12 UTC

Winsten

Visa Beats Expectations on Stronger Spending. The Stock Is Falling. -- Barrons.com

29 jan 2026, 21:55 UTC

Winsten

Micron Stock Rises. Samsung Signals a 'Golden Era' for Memory Chips. -- Barrons.com

29 jan 2026, 21:50 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

29 jan 2026, 21:50 UTC

Winsten

These Stocks Are Today's Movers: Microsoft, Meta, Tesla, Joby Aviation, SAP, Royal Caribbean, and More -- Barrons.com

29 jan 2026, 21:50 UTC

Marktinformatie
Winsten

Health Care Roundup: Market Talk

29 jan 2026, 21:50 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

29 jan 2026, 21:49 UTC

Winsten

Honeywell Delivers Solid Earnings Ahead of Its Corporate Breakup -- Barrons.com

29 jan 2026, 21:46 UTC

Winsten

Apple Posts Blowout iPhone Sales on Surging China Demand -- Update

29 jan 2026, 21:36 UTC

Winsten

Lockheed Martin Stock Jumps on Guidance and Government Missile Deal -- Barrons.com

29 jan 2026, 21:32 UTC

Winsten

Visa Beats Expectations on Stronger Spending. The Stock Is Falling. -- Barrons.com

29 jan 2026, 21:32 UTC

Winsten

Sandisk Beats Earnings. The Stock Is Soaring. -- Barrons.com

29 jan 2026, 21:30 UTC

Winsten

Apple Posts Blowout IPhone Sales on Surging China Demand -- WSJ

29 jan 2026, 21:30 UTC

Winsten

Apple 1Q Mac Rev $8.39B >AAPL

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

-12.54% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 18 USD  -12.54%

Hoogste 18 USD

Laagste 18 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

4 ratings

0

Buy

4

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

76 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat